Monitor for future data readouts from the ANVS-25002 trial, as enhanced digital biomarker data could strengthen clinical endpoints and support regulatory strategy. No immediate financial impact expected.
ANVS drugs
ANVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $2.67entry
- T+1 · 8mo ago −2.62%α −0.88% · $2.60
- T+5 · 8mo ago −19.48%α −17.26% · $2.15
- T+20 · 7mo ago −29.96%α −37.58% · $1.87
- T+60 · 5mo ago −33.33%α −47.68% · $1.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoing open-label Parkinson’s disease trial (ANVS-25002). The technology enables real-time, passive monitoring of core PD symptoms using wearables, complementing biological biomarker data from skin-based alpha-synuclein testing to enhance trial precision and real-world evidence collection.
Key Facts
- Annovis Bio partnered with NeuroRPM to use its FDA-cleared AI platform for real-time monitoring of Parkinson’s symptoms (bradykinesia, tremor, dyskinesia) in the ANVS-25002 open-label study.
- The study is enrolling 500 patients; 90 have been enrolled so far.
- NeuroRPM’s platform uses wearable sensors for passive, continuous data collection in real-world settings.
- Annovis is also using a biomarker test for misfolded phosphorylated alpha-synuclein with >90% sensitivity and specificity.
- Data from both digital and biological biomarkers will be used to assess symptom changes and potential disease modification.
Financial Impact
No financial terms disclosed; likely low-cost operational enhancement
Risk Factors
- Integration challenges with new digital platform may affect data consistency.
- No guarantee that improved monitoring will translate into positive clinical outcomes or regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258883 |
Track record
19 reports on ANVS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers